Blue Chip Partners’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $43M | Buy |
35,891
+444
| +1% | +$454K | 2.72% | 11 |
|
|
2026
Q1 | $32.6M | Buy |
35,447
+262
| +0.7% | +$266K | 2.35% | 13 |
|
|
2025
Q4 | $37.8M | Buy |
35,185
+11,356
| +48% | +$10.9M | 2.74% | 9 |
|
|
2025
Q3 | $18.2M | Buy |
23,829
+3,974
| +20% | +$2.96M | 1.36% | 31 |
|
|
2025
Q2 | $15.5M | Buy |
19,855
+2,837
| +17% | +$2.2M | 1.26% | 31 |
|
|
2025
Q1 | $14.1M | Buy |
17,018
+1,450
| +9% | +$1.21M | 1.21% | 29 |
|
|
2024
Q4 | $12M | Buy |
15,568
+287
| +2% | +$238K | 1.03% | 36 |
|
|
2024
Q3 | $13.5M | Buy |
15,281
+372
| +2% | +$334K | 1.18% | 30 |
|
|
2024
Q2 | $13.5M | Buy |
14,909
+1,115
| +8% | +$892K | 1.25% | 35 |
|
|
2024
Q1 | $10.7M | Buy |
13,794
+12,002
| +670% | +$8.54M | 1.04% | 35 |
|
|
2023
Q4 | $1.04M | Buy |
1,792
+3
| +0.2% | +$1.75K | 0.11% | 71 |
|
|
2023
Q3 | $961K | Sell |
1,789
-14
| -0.8% | -$7.21K | 0.11% | 69 |
|
|
2023
Q2 | $845K | Buy |
1,803
+38
| +2% | +$15.9K | 0.1% | 85 |
|
|
2023
Q1 | $606K | Sell |
1,765
-26
| -1% | -$8.77K | 0.07% | 89 |
|
|
2022
Q4 | $655K | Sell |
1,791
-37
| -2% | -$13.1K | 0.08% | 88 |
|
|
2022
Q3 | $591K | Buy |
1,828
+350
| +24% | +$111K | 0.08% | 77 |
|
|
2022
Q2 | $479K | Buy |
1,478
+13
| +0.9% | +$3.9K | 0.06% | 91 |
|
|
2022
Q1 | $420K | Buy |
1,465
+3
| +0.2% | +$772 | 0.05% | 98 |
|
|
2021
Q4 | $404K | Buy |
1,462
+3
| +0.2% | +$761 | 0.05% | 105 |
|
|
2021
Q3 | $337K | Buy |
1,459
+93
| +7% | +$23K | 0.05% | 104 |
|
|
2021
Q2 | $314K | Buy |
1,366
+3
| +0.2% | +$603 | 0.04% | 103 |
|
|
2021
Q1 | $255K | Buy |
1,363
+4
| +0.3% | +$782 | 0.04% | 110 |
|
|
2020
Q4 | $230K | Sell |
1,359
-117
| -8% | -$17.5K | 0.04% | 106 |
|
|
2020
Q3 | $218K | Sell |
1,476
-38
| -3% | -$5.88K | 0.04% | 97 |
|
|
2020
Q2 | $249K | Buy |
1,514
+4
| +0.3% | +$614 | 0.05% | 90 |
|
|
2020
Q1 | $209K | Sell |
1,510
-1,052
| -41% | -$145K | 0.05% | 89 |
|
|
2019
Q4 | $337K | Sell |
2,562
-501
| -16% | -$58.1K | 0.06% | 107 |
|
|
2019
Q3 | $342K | Buy |
3,063
+585
| +24% | +$65.1K | 0.07% | 99 |
|
|
2019
Q2 | $275K | Buy |
2,478
+11
| +0.4% | +$1.29K | 0.06% | 103 |
|
|
2019
Q1 | $320K | Buy |
2,467
+13
| +0.5% | +$1.58K | 0.08% | 101 |
|
|
2018
Q4 | $284K | Buy |
2,454
+12
| +0.5% | +$1.34K | 0.07% | 113 |
|
|
2018
Q3 | $262K | Buy |
2,442
+1
| +0% | +$100 | 0.06% | 103 |
|
|
2018
Q2 | $208K | Sell |
2,441
-142
| -5% | -$11.7K | 0.06% | 113 |
|
|
2018
Q1 | $200K | Buy |
+2,583
| New | +$208K | 0.06% | 123 |
|
Other funds holding LLY
Blue Chip Partners's LLY Position: Q2 2026 in Review
Blue Chip Partners increased its Eli Lilly (LLY) stake by 1.3% in Q2 2026, buying an estimated $454K and bringing the position to 35,891 shares worth $43M. The position accounts for 2.72% of the portfolio, ranked #11.
Blue Chip Partners first reported a position in LLY in Q1 2018 and has held it in 34 quarters since. 4,633 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Blue Chip Partners held 35,891 shares of Eli Lilly worth $43M as of Q2 2026.
- Blue Chip Partners bought 444 Eli Lilly shares in Q2 2026, an estimated $454K.
- Eli Lilly made up 2.72% of Blue Chip Partners's portfolio in Q2 2026, its #11 holding.
- Blue Chip Partners first reported a position in Eli Lilly in Q1 2018 and has held it in 34 quarters since.
- 4,633 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Blue Chip Partners's 13F filing for Q2 2026, filed 14 Aug 2026.